Key Highlights

  • Humana (NYSE:HUM) shares rose 4.17% to USD 395.86 on November 20, 2026.
  • TD Cowen upgraded to Buy and lifted its target to USD 485 from USD 430.
  • The stock fell about 13% on November 18 on the CRUSH rule.
  • Humana raised 2026 EPS guidance to at least USD 9.50.

Upgrade After a Sharp Medicare Advantage Sell-Off

Humana (NYSE:HUM), a health insurer with a large Medicare Advantage business, rose 4.17% to USD 395.86 on November 20, 2026. TD Cowen upgraded the stock to Buy and raised its target to USD 485 from USD 430, citing a path to meaningful EPS growth in 2027 and EPS above USD 40 in 2028. The rebound follows a drop of about 13% on November 18 on heavy volume, about three times the average, when managed-care stocks fell for a second session. The trigger was the proposed CRUSH rule from CMS, which would expand audit recoveries by extrapolating RADV findings across entire contracts back to payment year 2018, targeting about USD 9 billion of collections per payment year. The shares remain below their 52-week high of USD 462.87. Medicare Advantage plans receive fixed payments per member that are adjusted for how sick each member is, and RADV audits test whether the diagnoses behind those adjustments were documented. Extrapolation would let regulators apply error rates from a sample to every member under a contract, which is why the proposal moved the whole group.

Earnings Inflection and Policy Pressure

TD Cowen projects EPS rising from USD 9.51 in 2026 to USD 18.41 in 2027, with individual Medicare Advantage margins returning above 3%. Humana raised its 2026 EPS guidance to at least USD 9.50, and benefit cuts and pricing discipline support restored profitability. An investor update on December 10 and a comment deadline on January 19 are the next catalysts. Political pressure also adds uncertainty, including a Senate call to break up large insurers. The market Capitalization is USD 47.58 billion, the forward price to Earnings ratio is 22.31 and the trailing ratio is 38.49. The Dividend Yield is 0.90%. A higher trailing multiple shows how depressed current earnings are against expected ones. Humana depends more on Medicare Advantage than most large rivals, so a change to audit rules affects a larger share of its revenue. That concentration is part of why the stock fell harder than the group during the sell-off and may rebound faster if the rule is softened.

Risks: Reported Results Do Not Yet Show Recovery

The bearish view is that reported results do not yet show a recovery. Third quarter net Margin slipped to 0.394% from 0.597%, and the insurance segment lost USD 303 million, with a benefit ratio of 93.7% against 91.1% a year earlier. Management said it is too early to say where the 2027 margin will land, so investors pay a premium for improvement that has not yet been proven. Regulatory Risk from proposed CMS audits remains, and the final rule could differ from the proposal. After a rebound, valuation upside to price targets is also smaller. Investors will watch the December 10 update, the comment period and medical cost trends. The company has cut benefits and raised pricing discipline for 2026, but those actions can also reduce enrollment, and lower membership shrinks Revenue even when margins improve.

Where Things Stand

Humana (NYSE:HUM) rose because TD Cowen upgraded it to Buy after a 13% plunge tied to the CMS CRUSH proposal. Management's raised 2026 guidance and expected 2027 earnings growth support the rebound. Against that, third quarter margins fell, the insurance segment lost money and regulatory risk is unresolved. The December 10 update and January 19 comment deadline are next.